Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

In the Spotlight

Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived

Wade T. Iams and Christine M. Lovly
Wade T. Iams
1Division of Hematology/Oncology, McGaw Medical Center of Northwestern University, Chicago, Illinois.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine M. Lovly
2Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christine.lovly@vanderbilt.edu
DOI: 10.1158/2159-8290.CD-18-0489 Published July 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Summary: BLU-667 is a next-generation RET inhibitor that maximizes on-target and minimizes off-target effects. It is an exemplar of genotype-driven drug development followed by multi-histology basket trial validation that is becoming a paradigm for precision oncology. Cancer Discov; 8(7); 797–9. ©2018 AACR.

See related article by Subbiah et al., p. 836.

The identification and successful pharmacologic inhibition of oncogenic, constitutively active cellular kinases has been life-changing for many patients with cancer. Oncogenic kinase alterations occur in multiple ways, including point mutations, insertions/deletions, amplifications, and chromosomal rearrangements. Examples include point mutations in receptor tyrosine kinases (RTK) such as the EGFR, point mutations in intracellular kinases such as BRAF, amplifications in RTKs such as HER2, and chromosomal rearrangements in RTKs such as BCR–ABL, anaplastic lymphoma kinase (ALK), and ROS1.

In patients with non–small cell lung cancer (NSCLC), the step-wise refinement of drug development against the oncogenic kinases EGFR and ALK has demonstrated notable clinical benefits. For example, the recently reported FLAURA trial revealed that first-line therapy with the third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI) osimertinib more than doubles progression-free survival (PFS) compared with earlier-generation EGFR inhibitors in patients with advanced treatment-naïve EGFR-mutant NSCLC (1). Similarly, the ALEX trial demonstrated that first-line therapy with the “second-generation” ALK inhibitor alectinib more than doubled PFS compared with treatment with the “first-generation” ALK inhibitor crizotinib (25 months vs. 10 months, respectively; ref. 2). Similar drug development paradigms are under way for other targets, including ROS1, NTRK1/2/3, and RET. In this issue of Cancer Discovery, Subbiah and colleagues describe the development of a “next-generation” RET inhibitor, BLU-667, that is entering the analogous field of increasing the specificity of target kinase inhibition in patients with RET-driven malignancies (3).

The RET gene encodes for an oncogenic RTK found in a variety of cancers (4). Constitutive activation of RET can occur through point mutations, either in the extracellular domain or in the kinase domain, or through chromosomal rearrangements. In patients with medullary thyroid cancer (MTC), RET is characteristically altered by activating point mutations, whereas in patients with NSCLC and papillary thyroid cancer (PTC), RET is characteristically altered through chromosomal rearrangements (Fig. 1). Pharmacologic inhibition of RET is currently achieved with multikinase inhibitors (MKI), such as vandetanib and cabozantinib, in patients with RET-driven MTC, PTC, and NSCLC.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

RET alterations by histology and mutation type with current RET Inhibitors. RET-driven cancers tend to harbor either chromosomal rearrangements or point mutations in the RET extracellular domain or tyrosine kinase domain. A variety of multikinase inhibitors have been applied in patients with RET-driven cancer; however, BLU-667 and LOXO-292 are two next-generation RET inhibitors now being broadly applied to patients whose tumors harbor these oncogenic RET alterations.

Subbiah and colleagues describe the strategic development and initial clinical deployment of a novel, next-generation RET-selective inhibitor, BLU-667 (3). Starting with a chemical library screen encompassing >10,000 kinase inhibitors of >60 different chemical scaffolds, the lead compound, BLU-667, was selected to maximize on-target efficacy against wild-type and oncogenic RET while maintaining selectivity toward the target. In subsequent studies in NSCLC and MTC cell lines, BLU-667 exhibited superior potency in vitro against various oncogenic RET alterations compared with the MKIs vandetanib, cabozantinib, and RXDX-105. The authors focused their in vitro toxicity evaluation on inhibition of VEGFR2, as excess VEGFR2 inhibition can result in hypertension, thrombosis, and hemorrhage. BLU-667 achieved greater selectivity for RET over VEGFR2 compared with vandetanib, cabozantinib, and RXDX-105.

Following their in vitro drug potency analyses, the authors show that BLU-667 inhibits MAPK signaling better than vandetanib, cabozantinib, and RXDX-105 in both murine and human cell line models of RET-driven cancer mediated by both chromosomal rearrangements and point mutations, including the common MKI RET resistance mutations V804L and V804M. The authors proceed to quantify the in vivo antitumor efficacy of BLU-667 in allografts and patient-derived xenografts (PDX) of RET-driven cancer mediated by both chromosomal rearrangements and point mutations, again including the common MKI RET resistance mutation V804L and one PDX from a patient with CCDC6–RET-positive colorectal cancer. The authors trace the antitumor effects to on-target MAPK pathway inhibition in on-treatment tumor lysates in the PDX model of KIF5B–RET fusion NSCLC. To evaluate off-target effects, in the KIF5B–RET fusion NSCLC PDX model the authors demonstrate that BLU-667 has significantly less anti-VEGFR2 effect than cabozantinib.

Building on their preclinical studies, the authors describe a phase I “basket” trial (NCT03037385) treating patients with advanced, unresectable RET-altered tumors with BLU-667. The authors describe antitumor responses in 4 patients, including a 47% tumor reduction after 11 months in a patient with TKI-naïve MTC, a 47% tumor reduction after 8 months in a patient with MTC who had progressed after vandetanib, a >30% tumor reduction after 16 weeks in a patient with TKI-naïve KIF5B–RET fusion NSCLC, and a 34% tumor reduction after 16 weeks in a patient with KIF5B–RET fusion NSCLC who had progressed on vandetanib and everolimus. These patients experienced grade 1 toxicities, including nausea, leukopenia, hyperphosphatemia, constipation, dry skin, and rash. In one of the patients with MTC, RET pathway inhibition was demonstrated by decreased DUSP6 and SPRY4 mRNA expression in on-treatment tumor biopsies after 28 days of therapy. We await publication of the full clinical data for a complete efficacy and toxicity evaluation.

This addition to the arsenal for managing RET-altered cancers is noteworthy in several regards. First, the authors describe a compelling story of tailored drug development for an area of need, RET-driven malignancies, with detailed preclinical analysis supporting the compound's development. Second, the authors document initial clinical activity in patients with RET-driven tumors across histology (MTC, NSCLC) and different types of RET alterations (activating point mutations, rearrangements). Third and most notably, the strategic design of this drug, focusing on minimizing VEGFR2 “off-target” inhibition, is anticipated to decrease the frequency and severity of vascular toxicities (hypertension, thrombosis, hemorrhage) which have been particularly problematic with the MKIs that target both RET and VEGFR2. For example, in one study with vandetanib, grade 3 or higher hypertension affected over half of patients (5). However, it is crucial that this is validated in a larger dataset, because only 4 patients are reported in this article.

These findings also raise interesting questions for ongoing and future studies. First, as “next-generation” RET inhibitors are developed, what is the optimal sequence of RET TKI therapy? In addition to BLU-667, other, more selective inhibitors are being developed, including LOXO-292 (NCT03157128). Will response rates and resistance mechanisms change based on the line of therapy in which a specific RET TKI is received? Will there be a role for earlier-generation MKIs, which target RET and possibly other kinases that allow therapeutic escape?

Second, will the efficacy of BLU-667 and other “next-generation” RET inhibitors cross all histologies of RET-altered tumors? The more common RET-altered tumors were studied here, including MTC and NSCLC; however, RET alterations are found at low frequency across a broad variety of tumor types (Fig. 1). As oncologic care is rapidly integrating site-agnostic therapies, such as the recent FDA approval of pembrolizumab in microsatellite-unstable tumors (6) and breakthrough therapy designation for entrectinib in patients with NTRK-rearranged malignancies (7), it is still critical to consider tumor site of origin. We make particular note of BRAFV600E mutations, which are also found across a variety of tumor types. BRAFV600E inhibitors, such as vemurafenib and dabrafenib, achieve high response rates in BRAF-mutant melanoma (8). In contrast, similar responses are not observed in BRAF-mutant colorectal cancer, where upstream EGFR can provide primary resistance to BRAF inhibitors (9). Time will tell whether tissue site of origin will be critical in mediating the efficacy of RET inhibitors.

Third, will all genomic RET alterations be equally inhibited by BLU-667 and other “next-generation” RET inhibitors? When the clinical context of a target includes multiple genomic alteration types, such as chromosomal rearrangements and point mutations, it is critical to prove drug efficacy in preclinical development in all scenarios before proceeding to broad human testing. Although differences in drug efficacy based on different mutations have been demonstrated in patients with EGFR-mutant NSCLC, differences in drug efficacy based on chromosomal rearrangement fusion partners remain inadequately understood, as demonstrated by the remaining controversy in patients with ALK-rearranged NSCLC (10). The initial studies presented herein suggest that BLU-667 retains broad sensitivity against both RET mutations and RET fusions; however, more nuanced differences regarding degrees of sensitivity across different alterations within this target remain to be defined. It is also likely that mechanisms of acquired resistance to BLU-667 will differ based on the genomic and potentially histologic context.

In conclusion, next-generation TKIs applied in patients with EGFR- and ALK-driven NSCLC have shown impressive improvements in efficacy and acceptable toxicity profiles compared with earlier-generation inhibitors. We remain optimistic that a similar paradigm will play out for next-generation RET inhibitors such as BLU-667 in patients with RET-driven cancers.

Disclosure of Potential Conflicts of Interest

C.M. Lovly reports receiving commercial research support from Novartis, Xcovery, and AstraZeneca and is a consultant/advisory board member for Cepheid, Foundation Medicine, Takeda, Pfizer, Ariad, AstraZeneca, Novartis, Clovis, and Genoptix. No potential conflicts of interest were disclosed by the other author.

Acknowledgments

C.M. Lovly was supported by a Damon Runyon Clinical Investigator Award, a LUNGevity Career Development Award, a V Foundation Scholar-in-Training Award, an AACR-Genentech Career Development Award, a LCFA/IASLC Lori Monroe Scholarship, and by the NIH and NCI R01CA121210, U10CA180864, P01CA129243, and P30CA068485.

  • ©2018 American Association for Cancer Research.

References

  1. 1.↵
    1. Soria JC,
    2. Ohe Y,
    3. Vansteenkiste J,
    4. Reungwetwattana T,
    5. Chewaskulyong B,
    6. Lee KH,
    7. et al.
    Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113–25.
    OpenUrl
  2. 2.↵
    1. Peters S,
    2. Camidge DR,
    3. Shaw AT,
    4. Gadgeel S,
    5. Ahn JS,
    6. Kim DW,
    7. et al.
    Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017;377:829–38.
    OpenUrl
  3. 3.↵
    1. Subbiah V,
    2. Gainor JF,
    3. Rahal R,
    4. Brubaker JD,
    5. Kim JL,
    6. Maynard M,
    7. et al.
    Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov 2018;8:836–49.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kato S,
    2. Subbiah V,
    3. Marchlik E,
    4. Elkin SK,
    5. Carter JL,
    6. Kurzrock R
    . RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res 2017;23:1988–97.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Yoh K,
    2. Seto T,
    3. Satouchi M,
    4. Nishio M,
    5. Yamamoto N,
    6. Murakami H,
    7. et al.
    Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med 2017;5:42–50.
    OpenUrl
  6. 6.↵
    1. Le DT,
    2. Durham JN,
    3. Smith KN,
    4. Wang H,
    5. Bartlett BR,
    6. Aulakh LK,
    7. et al.
    Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–13.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Drilon A,
    2. Siena S,
    3. Ou SI,
    4. Patel M,
    5. Ahn MJ,
    6. Lee J,
    7. et al.
    Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov 2017;7:400–9.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Zhu Z,
    2. Liu W,
    3. Gotlieb V
    . The rapidly evolving therapies for advanced melanoma – towards immunotherapy, molecular targeted therapy, and beyond. Crit Rev Oncol Hematol 2016;99:91–9.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Corcoran RB,
    2. Andre T,
    3. Atreya CE,
    4. Schellens JHM,
    5. Yoshino T,
    6. Bendell JC,
    7. et al.
    Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 2018;8:428–43.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Lin JJ,
    2. Shaw AT
    . Differential sensitivity to crizotinib: Does EML4-ALK fusion variant matter?J Clin Oncol 2016;34:3363–5.
    OpenUrlFREE Full Text
View Abstract
PreviousNext
Back to top
Cancer Discovery: 8 (7)
July 2018
Volume 8, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived
Wade T. Iams and Christine M. Lovly
Cancer Discov July 1 2018 (8) (7) 797-799; DOI: 10.1158/2159-8290.CD-18-0489

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived
Wade T. Iams and Christine M. Lovly
Cancer Discov July 1 2018 (8) (7) 797-799; DOI: 10.1158/2159-8290.CD-18-0489
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • ATR Inhibition as an Attractive Therapeutic Resource against Cancer
  • Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas
  • Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors
Show more In the Spotlight
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement